Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress

In the adult brain, apolipoprotein E (apoE) mRNA is thought to be expressed by nonneuronal cells. Yet, when a brain damage has occurred, the protein is found in neurons. We have studied apoE expression following systemic kainic acid (KA), injected in rats to induce hippocampal neurodegeneration. We...

Full description

Bibliographic Details
Main Authors: U. Boschert, E. Merlo-Pich, Guy Higgins, A.D. Roses, S. Catsicas
Format: Article
Language:English
Published: Elsevier 1999-12-01
Series:Neurobiology of Disease
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996199902516
id doaj-799f29e38162464da6f56ee10cce172a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author U. Boschert
E. Merlo-Pich
Guy Higgins
A.D. Roses
S. Catsicas
spellingShingle U. Boschert
E. Merlo-Pich
Guy Higgins
A.D. Roses
S. Catsicas
Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
Neurobiology of Disease
author_facet U. Boschert
E. Merlo-Pich
Guy Higgins
A.D. Roses
S. Catsicas
author_sort U. Boschert
title Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
title_short Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
title_full Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
title_fullStr Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
title_full_unstemmed Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress
title_sort apolipoprotein e expression by neurons surviving excitotoxic stress
publisher Elsevier
series Neurobiology of Disease
issn 1095-953X
publishDate 1999-12-01
description In the adult brain, apolipoprotein E (apoE) mRNA is thought to be expressed by nonneuronal cells. Yet, when a brain damage has occurred, the protein is found in neurons. We have studied apoE expression following systemic kainic acid (KA), injected in rats to induce hippocampal neurodegeneration. We describe two effects. First, a moderate increase of apoE levels in astrocytes. Second, and unexpected, a very strong increase of apoE mRNA levels in clusters of CA1 and CA3 pyramidal neurons. Neuronal identity of these cells is supported by a series of observations. First, apoE hybridization signals were found in cells with morphological characteristics of pyramidal neurons. Second, the cells were positive for the neuronal marker MAP2. Third, the cells were negative for the astrocytic marker GFAP and for the microglia marker OX42. Fourth, the same distribution pattern was found with probes hybridizing to c-fos, a transcription factor transiently expressed in neurons under stress. At 48 and 72 h following KA, most of the excitotoxic cell death had already occurred. Since no morphological signs of programmed cell death were observed in apoE-positive pyramidal neurons, we suggest that expression of apoE by neurons may be part of a rescue program to counteract neurodegeneration.
url http://www.sciencedirect.com/science/article/pii/S0969996199902516
work_keys_str_mv AT uboschert apolipoproteineexpressionbyneuronssurvivingexcitotoxicstress
AT emerlopich apolipoproteineexpressionbyneuronssurvivingexcitotoxicstress
AT guyhiggins apolipoproteineexpressionbyneuronssurvivingexcitotoxicstress
AT adroses apolipoproteineexpressionbyneuronssurvivingexcitotoxicstress
AT scatsicas apolipoproteineexpressionbyneuronssurvivingexcitotoxicstress
_version_ 1724211447826743296
spelling doaj-799f29e38162464da6f56ee10cce172a2021-03-20T05:00:38ZengElsevierNeurobiology of Disease1095-953X1999-12-0166508514Apolipoprotein E Expression by Neurons Surviving Excitotoxic StressU. Boschert0E. Merlo-Pich1Guy Higgins2A.D. Roses3S. Catsicas4Geneva Biomedical Research Institute, 14 Chemin des Aulx, 1228, Geneva, Switzerland; Glaxo Ricerche, Verona, Italy; Neuroscience Unit, Glaxo Wellcome Medicine Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom; Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Box 2900, Duke University Medical Center, Durham, North Carolina, 27710; Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 9 Rue du Bugnon, 1005, Lausanne, SwitzerlandGeneva Biomedical Research Institute, 14 Chemin des Aulx, 1228, Geneva, Switzerland; Glaxo Ricerche, Verona, Italy; Neuroscience Unit, Glaxo Wellcome Medicine Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom; Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Box 2900, Duke University Medical Center, Durham, North Carolina, 27710; Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 9 Rue du Bugnon, 1005, Lausanne, SwitzerlandGeneva Biomedical Research Institute, 14 Chemin des Aulx, 1228, Geneva, Switzerland; Glaxo Ricerche, Verona, Italy; Neuroscience Unit, Glaxo Wellcome Medicine Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom; Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Box 2900, Duke University Medical Center, Durham, North Carolina, 27710; Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 9 Rue du Bugnon, 1005, Lausanne, SwitzerlandGeneva Biomedical Research Institute, 14 Chemin des Aulx, 1228, Geneva, Switzerland; Glaxo Ricerche, Verona, Italy; Neuroscience Unit, Glaxo Wellcome Medicine Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom; Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Box 2900, Duke University Medical Center, Durham, North Carolina, 27710; Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 9 Rue du Bugnon, 1005, Lausanne, SwitzerlandGeneva Biomedical Research Institute, 14 Chemin des Aulx, 1228, Geneva, Switzerland; Glaxo Ricerche, Verona, Italy; Neuroscience Unit, Glaxo Wellcome Medicine Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom; Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Box 2900, Duke University Medical Center, Durham, North Carolina, 27710; Institut de Biologie Cellulaire et de Morphologie, University of Lausanne, 9 Rue du Bugnon, 1005, Lausanne, SwitzerlandIn the adult brain, apolipoprotein E (apoE) mRNA is thought to be expressed by nonneuronal cells. Yet, when a brain damage has occurred, the protein is found in neurons. We have studied apoE expression following systemic kainic acid (KA), injected in rats to induce hippocampal neurodegeneration. We describe two effects. First, a moderate increase of apoE levels in astrocytes. Second, and unexpected, a very strong increase of apoE mRNA levels in clusters of CA1 and CA3 pyramidal neurons. Neuronal identity of these cells is supported by a series of observations. First, apoE hybridization signals were found in cells with morphological characteristics of pyramidal neurons. Second, the cells were positive for the neuronal marker MAP2. Third, the cells were negative for the astrocytic marker GFAP and for the microglia marker OX42. Fourth, the same distribution pattern was found with probes hybridizing to c-fos, a transcription factor transiently expressed in neurons under stress. At 48 and 72 h following KA, most of the excitotoxic cell death had already occurred. Since no morphological signs of programmed cell death were observed in apoE-positive pyramidal neurons, we suggest that expression of apoE by neurons may be part of a rescue program to counteract neurodegeneration.http://www.sciencedirect.com/science/article/pii/S0969996199902516